Association of p16 and Ki-67 with Risk of Recurrence in Previously Treated Cervical High-Grade Squamous Intraepithelial Lesions


Por: Arredondo-Galvez, Carlos German, Acuna-Gonzalez, Denise, Cantu-de-Leon, David, Chanona-Vilchis, Jose Gregorio, Aviles-Salas, Alejandro, Gonzalez-Enciso, Aaron, Bandala-Jaques, Antonio, Barquet-Munoz, Salim Abraham

Publicada: 1 jul 2021 Ahead of Print: 1 jun 2021
Resumen:
Objective: Our main objective was to assess the association between the markers p16 and Ki-67 and recurrence of disease in patients previously treated for cervical high-grade squamous intraepithelial lesion (HSIL). Design: This is a case-control study at the National Cancer Institute conducted between 2005 and 2015. Of the patients with a pathologically confirmed diagnosis of HSIL, 107 cases were selected. They were divided into 2 groups: 28 cases with recurrence after treatment and a control group of 79 patients without recurrence. We identified clinical, pathological, and treatment variables. Methods: Two experienced pathologists performed immunohistochemical analysis of biomarkers; they agreed on their interpretation, and we calculated the odds ratios (ORs) associated with recurrence. For group comparisons, we used the Wilcoxon signed-rank, chi(2), or Fisher's exact test, depending on the type of variable. We conducted logistic regression models to estimate ORs and determine the factors associated with recurrence. The recurrence-free period was defined as the time frame between conization and either recurrence of disease or the last date the patient was seen. We used Kaplan-Meier plots to visualize survival curves and log-rank tests to compare the curves. We established a p value Results: After pathologists performed immunohistochemical analysis, they achieved an agreement level of 83.7% for p16 and 60% for Ki-67. We did not find an association between recurrence and either p16 expression (p = 0.69) or the percentage of Ki-67 expression (p = 0.71). The recurrence-free period analysis did not reveal a difference in p16 expression (p = 0.57) nor in the percentage of Ki-67 expression in the 3-tiered scale (p = 0.56). Limitations: Our main limitation was a reduced sample size. Conclusion: We found no association between p16 and Ki-67 positivity and the risk of recurrence in previously treated HSIL.

Filiaciones:
Arredondo-Galvez, Carlos German:
 Inst Nacl Cancerol, Dept Ginecol, Mexico City, DF, Mexico

Acuna-Gonzalez, Denise:
 Ctr Med Naval, Dept Ginecol, Mexico City, DF, Mexico

Cantu-de-Leon, David:
 Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City, DF, Mexico

 Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico

Aviles-Salas, Alejandro:
 Inst Nacl Cancerol, Dept Patol, Mexico City, DF, Mexico

Gonzalez-Enciso, Aaron:
 Inst Nacl Cancerol, Subdirecc Cirugia, Mexico City, DF, Mexico

Bandala-Jaques, Antonio:
 Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City, DF, Mexico

 Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico

Barquet-Munoz, Salim Abraham:
 Inst Nacl Cancerol, Dept Ginecol, Mexico City, DF, Mexico
ISSN: 03787346





GYNECOLOGIC AND OBSTETRIC INVESTIGATION
Editorial
KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 86 Número: 3
Páginas: 293-298
WOS Id: 000662286700001
ID de PubMed: 34111875